High rates of JCV seroconversion in a large international cohort of natalizumab-treated patients

High rates of JCV seroconversion in a large international cohort of natalizumab-treated patients

Aims: To retrospectively assess factors associated with John Cunningham virus (JCV) seroconversion in natalizumab-treated patients. Background: Natalizumab is highly effective for the treatment of relapsing–remitting multiple sclerosis (RRMS), but its use is complicated by opportunistic JCV infectio...

Full description

Bibliographic Details
Main Authors: Christopher M. Dwyer, Vilija G. Jokubaitis, Jim Stankovich, Josephine Baker, Jodi Haartsen, Helmut Butzkueven, Adriana Cartwright, Neil Shuey, Yara Dadalti Fragoso, Louise Rath, Olga Skibina, Kylie Fryer, Ernest Butler, Jennifer Coleman, Jennifer MacIntrye, Richard Macdonell, Anneke van der Walt
Format: Article
Language:English
Published: SAGE Publishing 2021-04-01
Series:Therapeutic Advances in Neurological Disorders
Online Access:https://doi.org/10.1177/1756286421998915

Internet

https://doi.org/10.1177/1756286421998915

Similar Items